首页> 外文期刊>Cerebrovascular diseases >When to Screen Ischaemic Stroke Patients for Cancer
【24h】

When to Screen Ischaemic Stroke Patients for Cancer

机译:什么时候筛查缺血性脑卒中患者癌症

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background and Purpose: Ischemic stroke can be the first manifestation of cancer and it is therefore important to ascertain which stroke patients should be considered for cancer-diagnostic investigations. We aimed to determine the frequency of active cancer in patients with acute ischemic stroke and to compare clinical findings in stroke patients with active cancer to ischemic stroke patients with no history of cancer. Finally, we aimed to develop a predictive and feasible score for clinical use to uncover underlying malignancy. Methods: All ischemic stroke patients admitted to the stroke unit in the Department of Neurology, Haukeland University Hospital were consecutively included in the Norwegian Stroke Research Registry (NORSTROKE). Stroke etiology was determined by the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria. Data on cancer diagnoses was obtained from patients' medical records and the Cancer Registry of Norway. Active cancer was defined as cancer diagnosis, metastasis of known cancer, recurrent cancer or receiving cancer treatment, all within 12 months before or after the index stroke. Based on variables independently associated with active cancer, a predictive score was developed using the area under the receiver operating characteristic (AUCROC) curves. Bayes' theorem was used to calculate post-test probabilities of active cancer. Results: Of the 1,646 ischemic stroke patients included, 82 (5.0%) had active cancer. Increased D-dimer (OR = 1.1, 95% CI: 1.1-1.2, p = 0.001), lower Hb (OR = 0.6, 95% CI: 0.5-0.7, p = 0.001), smoking (OR = 2.2, 95% CI: 1.2-4.3, p = 0.02) and suffering a stroke of undetermined etiology (OR = 1.9, 95% CI: 1.1-3.3, p = 0.03) were factors independently associated with active cancer. These were included in the final predictive score which gave an AUC of 0.73 (95% CI: 0.65-0.81) in patients younger than 75 years of age. Assuming the prevalence of cancer to be 5%, the score shows that if a patient fulfills all 3 score points, the probability of active cancer is 53%. Conclusions: Active cancer was found in 5% of our ischemic stroke patients. We found that a clinical score comprising elevated D-dimer = 3 mg/L, lower Hb = 12.0 g/dL and previous or current smoking is feasible for predicting active cancer in ischemic stroke patients. (c) 2018 S. Karger AG, Basel
机译:背景和目的:缺血性卒中可以是癌症的第一个表现,因此重要的是要确定哪种中风患者应考虑癌症诊断调查。我们的旨在确定急性缺血性卒中患者中活性癌症的频率,并将中风患者的临床发现与缺血性脑卒中患者无癌症患者进行比较。最后,我们旨在为临床用途制定预测性和可行的分数,以发现潜在的恶性肿瘤。方法:所有缺血性脑卒中患者患有神经病学系中的中风部门,都在挪威中风研究登记处(Norstroke)。通过在急性中风治疗(吐司)标准中的ORG 10172的试验确定行程病因。癌症诊断数据是从患者的病历和挪威癌症登记处获得的。活性癌症被定义为癌症诊断,已知癌症的转移,复发性癌症或接受癌症治疗,在指数卒中前12个月内或之后。基于与活性癌症独立相关的变量,使用接收器操作特性(AUCROC)曲线下的区域开发了预测得分。贝叶斯定理用于计算活性癌症的测试后概率。结果:1,646名缺血性脑卒中患者包括82名(5.0%)有活跃的癌症。增加D-二聚体(或= 1.1,95%CI:1.1-1.2,P = <0.001),低温Hb(或= 0.6,95%Ci:0.5-0.7,P = <0.001),吸烟(或= 2.2,95%CI:1.2-4.3,p = 0.02)并患有未确定病因的中风(或= 1.9,95%CI:1.1-3.3,P = 0.03)是与活性癌有关的因素。这些患者包含在比75岁以下的患者中的最终预测得分为0.73(95%CI:0.65-0.81)。假设癌症的患病率为5%,分数表明,如果患者满足所有3个得分点,则活性癌症的可能性为53%。结论:在5%的缺血性卒中患者中发现了活性癌症。我们发现,包括升高的D-二聚体= 3mg / L,下部Hb = 12.0g / dl以及之前或电流吸烟的临床评分是可行的,可用于预测缺血性卒中患者的活性癌症。 (c)2018年S. Karger AG,巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号